Sector News

Actavis job-cutting drive hits 400-plus on Long Island

March 18, 2015
Life sciences
New-look Actavis–soon to be Allergan–has been undergoing plenty of changes since it agreed in November to shell out $66 billion for the Botox maker. And as it continues to integrate Allergan’s ops, it’s shaving away at the workforce it inherited from its prior pickup, Forest Labs.
 
Last week, the company updated its Long Island, NY, jobs toll to 412, with the bulk of those in commercial packaging operations. Forty-seven of the job-cutting total are sales staffers who work remotely, according to a New York state WARN notice.
 
Actavis first announced the layoffs back in September, and since then it’s gotten to work trimming Forest’s ranks in other states, too. Last July, it delivered pink slips to 190 workers in Earth City, MO, after deciding to close a facility there. And in December, it said it would cut loose 200 more in Corona, CA, an area that’s been part of a gradual drawdown.
 
What Actavis hasn’t yet said, though, is whether, which and when employees will face the ax as a result of its Allergan tie-up. The deal, which added 11,500 staffers to the 25,000 employees Actavis already had, closed this week after clearing its final regulatory hurdle
 
But word on any forthcoming scale-back could be coming sooner rather than later. The Dublin drugmaker has pledged $1.8 billion in cost savings–the majority of which are due within the next year.
 
By Carly Helfand
 

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend